

**choriogonadotropin alfa 250 mcg/0.5 ml pre-filled syringe
(Ovitrelle[®]) (No. 264/06)**

Serono Ltd

Product Update

8 September 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

choriogonadotropin alfa 250 mcg/0.5 ml pre-filled syringe (Ovitrelle[®]) is accepted for use in NHS Scotland for the treatment of anovulatory or oligo-ovulatory women, where the use of this preparation is appropriate.

Unlike the vial formulation available previously it does not require reconstitution, and the cost per dose is the same.

This replaces advice previously issued by the Scottish Medicines Consortium for Ovitrelle in May 2006 following a non-submission.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 10 July 2006.

**Chairman,
Scottish Medicines Consortium**